Eloisa Jantus Lewintre

Profesora titular

Universitat Politècnica de València

Spain

Research Interests

Explore related searches

Professors in Spain Professors in Immunology Immunology professors in Spain

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Eloisa Jantus Lewintre is a Profesora titular at Universitat Politècnica de València, Spain. Her research focuses on molecular profiling and therapeutic strategies in non-small cell lung cancer (NSCLC), particularly involving KRAS and BRAF mutations. She has contributed to advancing quality control frameworks in liquid biopsy applications and exploring drug vulnerabilities driven by metabolic reprogramming.

Articles (20)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2021

Collaborators (8)

Alejandro Vignoni

Ass. Professor (Tenure)

Universitat Politècnica de València

SPAIN

Instituto de Investigación Sanitaria Aragón

SPAIN

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Eloisa Jantus Lewintre

Research Interests

Explore related searches

Contact this professor

About

Articles (20)

High-fidelity Cas9-mediated targeting of KRAS driver mutations restrains lung cancer in preclinical models

Role of the International Society of Liquid Biopsy (ISLB) in establishing quality control frameworks for clinical integration

Multicenter In-House Evaluation of an Amplicon-Based Next−Generation Sequencing Panel for Comprehensive Molecular Profiling

Cross-method comparison for BRAF p.V600 mutation cfDNA testing in Melanoma: BRAFI study

Cross-method comparison for BRAF p.V600 mutation cfDNA testing in Melanoma: BRAFI study

NNMT-driven metabolic reprogramming creates a NAMPT druggable vulnerability and reveals liquid biopsy biomarkers for TKI resistance in EGFR-mutant NSCLC

Targeted delivery of therapeutics to metastatic lung cancer cells using aptamer-conjugated nanoemulsions

G9a/DNMT1 co-targeting inhibits non-small cell lung cancer growth and reprograms tumor cells to respond to cancer-drugs through SCARA5 and AOX1.

<i>KRAS</i>-mutant non-small cell lung cancer (NSCLC) therapy based on tepotinib and omeprazole combination

HMGB1 Expression Levels Correlate with Response to Immunotherapy in Non-Small Cell Lung Cancer

Advancements in synthetic biology-based bacterial cancer therapy: A modular design approach

Soluble galectin‐3 as a microenvironment‐relevant immunoregulator with prognostic and predictive value in lung adenocarcinoma

Biological insights in non-small cell lung cancer

On the Oral Microbiome of Oral Potentially Malignant and Malignant Disorders: Dysbiosis, Loss of Diversity, and Pathogens Enrichment

A Sonic Hedgehog Pathway Score to Predict the Outcome of Resected Non-Small Cell Lung Cancer Patients

ASO Author Reflections: Key Components of the Hedgehog Signaling Pathway as Prognostic Biomarkers in Non-small Cell Lung Cancer

ASO Visual Abstract: A Sonic Hedgehog Pathway Score to Predict the Outcome of Resected Non-small Cell Lung Cancer Patients

Clinical and technical insights of tumour mutational burden in non-small cell lung cancer

Analysis of Exosomal Cargo Provides Accurate Clinical, Histologic and Mutational Information in Non-Small Cell Lung Cancer

Liquid Biopsy from research to clinical practice: focus on Non-Small Cell Lung Cancer

Collaborators (8)

Alejandro Vignoni

Carlos Camps

Rafael Sirera

Jesus M Paramio

Ruben Pio

David Hervas

EVA SERNA GARCIA

Andrea Moreno Manuel

Make your next move.